Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial

Patients who develop steroid-refractory acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic cell transplantation have poor prognosis, highlighting an unmet therapeutic need. In this open-label phase 2 study (ClinicalTrials.gov identifier: NCT02953678), patients aged at least 12 ye...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Jagasia, Madan, Perales, Miguel-Angel, Schroeder, Mark A., Ali, Haris, Shah, Nirav N., Chen, Yi-Bin, Fazal, Salman, Dawkins, Fitzroy W., Arbushites, Michael C., Tian, Chuan, Connelly-Smith, Laura, Howell, Michael D., Khoury, H. Jean
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2020
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7229262/
https://ncbi.nlm.nih.gov/pubmed/32160294
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020004823
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados